BSE · 524548
Sharma East India Hosp and Medical Research Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹30 Cr with net profit ₹1 Cr — a 4.12% net margin, versus 2.78% the period before.
Shareholding
As of 2026-06-30
- Promoter53.63%
- Public46.37%
4,211 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 15.59× from low to high.
Risk flags
Derived from disclosed data
- 52-week range spans 15.59× (₹15 to ₹233.9) — an unusually wide band.
Peer comparison
Healthcare · ranked #44 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.07 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.34 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 135.03 | 8.94 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Sharma East India Hosp and Medical Research Ltd.(this company) | ₹33 Cr | 26.62 | 2.58 | 9.06% | 3.48% |
AI analysis
AI-generated · google/gemini-2.5-flashSharma East India Hosp and Medical Research Ltd. (symbol: SHARMAEASTINDIAHOSPITA) has a market capitalization of Rs 33 Cr. The company has a PE ratio of 26.33 and an EPS of 3.79. The book value per share is 39.15. For the financial year ending March 2025, revenue was Rs 30.1859 Cr and net profit was Rs 1.2443 Cr.
Positives
- +The profit margin is 347.9%, indicating high profitability.
- +Debt-to-equity ratio is 0.31, suggesting a low level of debt.
- +Promoter shareholding is 53.633%, which indicates significant insider ownership and no shares are pledged (0%).
Negatives
- −No dividend yield (0%) has been reported, which may be a concern for income-focused investors.
- −Revenue growth for Mar 2025 is not available.
- −Return on equity (ROE) is 9.06% and return on capital employed (ROCE) is 9.8779%, which might be considered moderate.
- −No quarterly EPS figures are available in the provided data.
- −No quarterly results have been disclosed since Mar 2026.
Financial performance
Revenue increased from Rs 10.9634 Cr in Mar 2021 to Rs 30.1859 Cr in Mar 2025. Net profit also showed growth, rising from Rs 0.6372 Cr in Mar 2021 to Rs 1.2443 Cr in Mar 2025. Earnings per share (EPS) grew from 1.94 in Mar 2021 to 3.79 in Mar 2025, though there was a dip to 2.02 in Mar 2024 from 2.96 in Mar 2023.
Profitability & returns
The company reported a profit margin of 347.9%. Return on equity (ROE) was 9.06% and return on capital employed (ROCE) was 9.8779%. These figures indicate the company's ability to generate profit from its revenue and efficiently use its equity and capital.
Balance sheet
The debt-to-equity ratio is 0.31, indicating a relatively low reliance on debt for financing. The book value per share stands at Rs 39.15, which is lower than the current share price based on the implied market cap and EPS figures.
Ownership & pledges
The public shareholding stands at 46.367%. There is no reported promoter pledge (0%), indicating that promoters have not collateralized their holdings. No shares are held by DIIs or FIIs.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Sharma East India Hosp and Medical Research Ltd.share price & fundamentals